AzTrials
AzTrials

Anal FistulaNCT00951002

The Efficacy of Human Acellular Dermal Matrix in the Treatment of Anal Fistula

An observational study of Anal Fistula and Treatment, run by Zhen Jun Wang at 13 sites in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record

Search all trials

Trial summary

The purpose of this study is to determine whether human acellular dermal matrix plug is effective in the treatment of anal fistula Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
acellular dermal matrix plug
Type of treatment
Surgery or procedure
How many people
1,000 participants
Where
13 sitesChina
Study dates
Jul 2009to Nov 2013
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: hospitalized patients with complex anal fistula

Who may be able to join

  • complex anal fistula

Who cannot join

  • pregnancy or lactation
  • with operation contraindication
  • allergic constitution to heterogeneous protein
  • complicated with tumor
  • complicated with acute infection

Trial locations and contacts

13 sites in 1 country.

Zhen Jun Wang, M.D. contact

86-013601393711

wang3zj@sohu.com

Jia Gang Han, M.D. contact

86-013522867841

wzhj611@163.com

13 sites in 1 country

China13 sites, 13 recruiting
  • Beijing Anorectal Hospital

    Beijing, Beijing Municipality, 100000

    Chang Shun Wang, M.D.

    Chang Shun Wang, M.D.

    Recruiting
  • Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

    Beijing, Beijing Municipality, 100000

    Bao Ming Zhao, M.D.

    Bao Ming Zhao, M.D.

    Recruiting
  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100000

    Chao Wen Chen, M.D., 86-013901038133

    Chao Wen Chen, M.D.

    Recruiting
  • The Central Hospital of China Aerospace Corporation

    Beijing, Beijing Municipality, 100000

    Li Yong Wang, M.D.

    Li Yong Wang, M.D.

    Recruiting
  • The Second Artillery General Hospital

    Beijing, Beijing Municipality, 100000

    Ke Zhao, M.D., 86-013370120126

    Ke Zhao, M.D.

    Recruiting
  • General Surgery, Beijing Chao Yang Hospital

    Beijing, Beijing Municipality, 100020

    Zhen Jun Wang, M.D., 86-013601393711, wang3zj@sohu.com

    Jia Gang Han, M.D., 86-013522867841, hjg512@yahoo.com.cn

    Recruiting
  • Shandong Provincial Hospital

    Jinan, Shandong, 250000

    Xue Zhi Xin, M.D., 86-013553173016

    Xue Zhi Xin, M.D.

    Recruiting
  • The Second Affiliated Hospital of Medical College Shandong University

    Jinan, Shandong

    Ke Ding, M.D.

    Ke Ding, M.D.

    Recruiting
  • The 85th Hosptial of P.L.A

    Shanghai, Shanghai Municipality, 200000

    Min Kong', M.D.

    Min Kong, M.D.

    Recruiting
  • Shenyang Anorectal Hospital

    Shenyang, Liaoning, 110000

    Xian Dong Zeng, M.D., 86-013940188858

    Xian Dong Zeng, M.D.

    Recruiting
  • Shenzhen People's Hospital

    Shenzhen, Guangdong, 518000

    Xiao Dong Yang, M.D., 86-013602643196

    Xiao Dong Yang, M.D.

    Recruiting
  • Hebei Children's Hospital

    Shijiazhuang, Hebei, 050000

    Li Ya Wang, M.D.

    Li Ya Wang, M.D.

    Recruiting
  • General Staff Hospital of Wuhan Iron and Steel (Group) Corp

    Wuhan, Hubei, 430000

    Guang Wei Si Tu, M.D.

    Guang Wei Si Tu, M.D.

    Recruiting

Other trials in China

About this study

Official title: A Multicenter Clinical Trial to Evaluate the Efficacy of Human Acellular Dermal Matrix in the Treatment of Anal Fistula

The purpose of this study is to determine whether human acellular dermal matrix plug is effective in the treatment of anal fistula

Read the detailed description

Recently, the use of biomaterial for the treatment of anal fistula has drawn great interest. The advantages of this technique include simple and repeatable application, preservation of sphincter integrity, minimal patient discomfort, and the ability for subsequent surgical options if needed. Champagne et al reported using a biologic absorbable anal fistula plug which is made from lyophilized porcine small intestinal submucosa (Surgisis®). In their series of 46 patients treated with the anal fistula plug, a success rate of 83 percent was achieved at a median follow-up of 12 months. In addition, evaluation of the functional outcome after fistula closure showed no impairment of continence with significant improvement in quality of life showed. However, the long term success rates of Surgisis® are variable according to other studies.

Human acellular dermal matrix (ADM) is a biologic material consists of dermis without its cellular components. Early and rapid revascularization of the implanted ADM, as was shown in our previous experimental study, is thought to enhance resistance to infection and contamination. These properties make ADM an attractive alternative for the treatment of anal fistula. The ability of ADM to become vascularized and remodeled by autologous cells may be advantageous for anal fistulas healing.

The purpose of this study is to determine whether human acellular dermal matrix plug is effective in the treatment of anal fistula.

Being tested
acellular dermal matrix plug
Keywords
anal fistula, acellular dermal matrix, treatment, postoperative complications, recurrence
Medical subject headings
Rectal Fistula, Postoperative Complications, Recurrence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • acellular dermal matrix plugProcedure or surgery

    Also called Ruinuo

    anal fistula treated with human acellular dermal matrix plug

Study groups in NCT00951002
Study groupRoleWhat they receive
acellualr dermal matrixpatients treated with acellular dermal matrix plug
Receives: Procedure: acellular dermal matrix plug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. postoperative complications

    Measured: 01/07/2011

Secondary outcomes (1)
  1. recurrence rate

    Measured: 01/07/2011

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2009 (estimated)
  2. Study startJul 2009
  3. Primary completionNov 2013 (estimated)
  4. Study completionNov 2013 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00951002
Sponsor's protocol ID
AF-HADM-01
Status last verified
Nov 2013
First submitted
31 Jul 2009
Last updated
27 Nov 2013
Results posted
No
Data monitoring committee
Yes

Publications

  • Han JG, Xu HM, Song WL, Jin ML, Gao JS, Wang ZJ, Yang XQ. Histologic analysis of acellular dermal matrix in the treatment of anal fistula in an animal model. J Am Coll Surg. 2009 Jun;208(6):1099-106. doi: 10.1016/j.jamcollsurg.2009.02.052. Epub 2009 Apr 24.

    PubMed 19476898
  • Song WL, Wang ZJ, Zheng Y, Yang XQ, Peng YP. An anorectal fistula treatment with acellular extracellular matrix: a new technique. World J Gastroenterol. 2008 Aug 14;14(30):4791-4. doi: 10.3748/wjg.14.4791.

    PubMed 18720541

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in